Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC‐0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor.

MLA

Herman, Ann E., et al. “Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC‐0853, a Selective Reversible Bruton’s Tyrosine Kinase Inhibitor.” Clinical Pharmacology & Therapeutics, vol. 103, no. 6, June 2018, pp. 1020–28. EBSCOhost, https://doi.org/10.1002/cpt.1056.

APA

Herman, A. E., Chinn, L. W., Kotwal, S. G., Murray, E. R., Zhao, R., Florero, M., Lin, A., Moein, A., Wang, R., Bremer, M., Kokubu, S., Serone, A. P., Morimoto, A. M., Winter, H. R., Katsumoto, T. R., Hanze, E. L., & Viberg, A. (2018). Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC‐0853, a Selective Reversible Bruton’s Tyrosine Kinase Inhibitor. Clinical Pharmacology & Therapeutics, 103(6), 1020–1028. https://doi.org/10.1002/cpt.1056

Chicago

Herman, Ann E., Leslie W. Chinn, Shweta G. Kotwal, Elaine R. Murray, Rui Zhao, Marilyn Florero, Alyse Lin, et al. 2018. “Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC‐0853, a Selective Reversible Bruton’s Tyrosine Kinase Inhibitor.” Clinical Pharmacology & Therapeutics 103 (6): 1020–28. doi:10.1002/cpt.1056.